Tag: acute lymphoblastic leukemia (ALL)
1. In two phase 1 studies, allogenic anti-CD19 CAR T cell (UCART19) treatment showed a manageable safety profile with relapsed or refractory B-cell acute lymphoblastic leukemia.
2. Allogenic anti-CD19 T cells demonstrated antileukemic activity in both children and adults.
Evidence Rating Level: 2 (Good)
Study Rundown: Although autologous anti-CD19 chimeric antigen receptor...
1. Treatment with dasatinib and blinatumomab was associated with high incidence of molecular response in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL).
2. Treatment with dasatinib and blinatumomab for patients with Ph-positive ALL was associated with a high incidence of survival.
Evidence Rating Level: 2 (Good)
Study Rundown: Prognosis for...